Why Is Heparin So Hard to Find? [Explained for 2026]

If you or a loved one has been prescribed heparin and struggled to get it filled, you are not alone. Heparin has been on the FDA drug shortage list continuously since November 2017 — one of the longest-running active shortages of any medication in the United States. In 2026, the situation remains serious, with multiple manufacturers facing backorders, production delays, and even permanent product discontinuations. This guide explains exactly why heparin is so hard to find, which formulations are most affected, and what steps you can take right now.

What Is Heparin and Why Is It So Important?

Heparin is an injectable anticoagulant — commonly called a blood thinner — that prevents and treats dangerous blood clots. It is one of the most widely used medications in hospital settings, required for procedures ranging from cardiac surgery and dialysis to treating pulmonary embolism (PE) and deep vein thrombosis (DVT). Some estimates suggest that 50–70% of all hospitalizations require heparin in some form, making it second only to insulin in terms of how broadly and critically it is used in modern medicine.

For outpatients, heparin may be prescribed for home self-injection — for bridge therapy when transitioning to oral anticoagulants, during pregnancy in patients who cannot take warfarin, or for ongoing prophylaxis. When a pharmacy cannot fill this prescription, the consequences can be medically serious.

Is Heparin Currently on the FDA Shortage List?

Yes. As of 2026, heparin injection remains on the official FDA drug shortage list. The FDA first posted the heparin shortage in November 2017, and it has never fully resolved. Multiple formulations and strengths remain either on backorder or in limited allocation, depending on the manufacturer. The American Society of Health-System Pharmacists (ASHP) maintains a running shortage detail page confirming the ongoing supply disruptions across multiple brands.

Why Is Heparin So Hard to Find in 2026?

Several compounding factors have created the persistent heparin shortage. Understanding these root causes helps explain why this isn't a simple manufacturing problem that can be quickly fixed.

1. Heparin is derived from pig intestines — mostly sourced from China. Unlike synthetic drugs, heparin is extracted from the intestinal mucosa of pigs. Approximately 60% of the U.S. supply has historically come from China, where large-scale pig farming and processing infrastructure is concentrated. This creates a supply chain that is inherently vulnerable to geopolitical tensions, tariffs, disease outbreaks, and shipping disruptions. For a deeper look at what's happening right now, see our 2026 heparin shortage update for patients.

2. Multiple manufacturers have discontinued or reduced supply. Mylan (Viatris) permanently discontinued all heparin injection products in March and April 2025. Pfizer has temporarily discontinued several key formulations including 1,000 unit/mL 10 mL and 30 mL vials and 5,000 unit/mL vials, with Carpuject syringes now in limited weekly releases. Sagent has key vials on backorder with no firm release date, and Techdow USA is similarly backordered across multiple strengths.

3. Demand is extremely high and relatively inelastic. Because heparin is used in so many critical procedures — dialysis, cardiac surgery, stroke prevention — demand doesn't decrease just because supply is tight. Hospitals and clinics cannot simply stop using heparin; they must secure whatever supply is available, often at higher prices and from limited sources.

4. Manufacturing is complex, time-intensive, and difficult to scale quickly. Producing heparin requires specialized heavy-duty equipment to process massive quantities of pig intestinal tissue. The machinery is expensive, cannot be easily repurposed, and the multi-step extraction and purification process involves extensive quality controls. A new manufacturer cannot simply spin up production overnight.

5. U.S. tariffs on Chinese pharmaceutical imports are adding cost pressure. Proposed and enacted tariffs on imports from China have created additional uncertainty and cost pressure for manufacturers who rely on Chinese-sourced porcine mucosa. This is compounding existing supply chain vulnerabilities and raising the risk of further disruptions.

Which Heparin Formulations Are Most Affected?

Not all heparin formulations are equally affected. As of 2026, the most impacted include:

Pfizer Carpuject syringes (5,000 and 10,000 units/mL): In limited supply with weekly releases only; Pfizer also issued an important warning about a potential molding defect in certain Carpuject needle sheaths.

Sagent 1,000 units/mL 10 mL vials: On backorder with estimated April 2026 release; 30 mL vials on limited allocation.

Techdow USA 10,000 and 20,000 units/mL vials: On backorder with no estimated release date.

More reliably available: Fresenius Kabi and Hikma formulations tend to have better availability in some regions, but stock can vary week to week.

37,598+ patients found their medications in stock

37K+

Find Heparin In Stock Today →

What Can Patients Do When Heparin Is Hard to Find?

If your pharmacy is unable to fill your heparin prescription, don't wait — anticoagulation gaps can be medically dangerous. Here are the most important steps to take:

Contact your prescriber immediately. Never skip doses of anticoagulation therapy without medical guidance. Your doctor may be able to prescribe a different formulation, strength, or an alternative medication.

Try multiple pharmacies. Availability varies significantly by pharmacy and region. A pharmacy 10 miles away may have stock when your local one doesn't. Independent pharmacies sometimes maintain stock that chain pharmacies have depleted.

Use medfinder. medfinder calls pharmacies near you to check which ones have your medication in stock, saving you hours of phone calls. You provide your medication, dosage, and ZIP code — we do the searching.

Ask about manufacturer substitution. Heparin sodium is a generic medication. If your pharmacy is out of one brand, a different manufacturer's product with the same strength is generally interchangeable (your doctor may need to approve the substitution).

Are There Alternatives to Heparin?

Yes, several alternatives exist depending on your condition and what your doctor determines is clinically appropriate. Low-molecular-weight heparins like enoxaparin (Lovenox), fondaparinux (Arixtra), and oral anticoagulants like apixaban (Eliquis) or rivaroxaban (Xarelto) are among the options your prescriber may consider. For a detailed breakdown, see our guide on alternatives to heparin if you can't fill your prescription. Always discuss any changes in anticoagulation therapy with your provider before making a switch.

Skip the calls, skip the stress.

Find Heparin In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Will the Heparin Shortage Be Resolved?

The structural challenges behind the heparin shortage — reliance on Chinese porcine mucosa, limited U.S. manufacturing capacity, and the complexity of the production process — mean that a quick resolution is unlikely. The FDA has indicated it will support development of non-porcine heparin alternatives, and some manufacturers are exploring synthetic sources. However, these solutions are years away from large-scale commercial availability.

In the meantime, patients and caregivers need practical tools to navigate the current shortage. medfinder was built precisely for situations like this — to help patients find their medication at a pharmacy that actually has it in stock, without spending hours on hold.